This is probably due to the tumor immune microenvironment of EGFR mutant NSCLC, which is associated with uninflamed characteristics, low PD-L1 (programmed death-ligand-1) expression/CD8+ TILs (Tumor-infiltrating lymphocytes), and a low tumor mutational burden (TMB) [108,109]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.